Comparing two eye injections for wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This study compares two eye injection treatments for wet age-related macular degeneration (AMD), a condition that causes vision loss. The trial aims to see if the new drug GNR-139 works as well as the standard treatment Eylea.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years or older.
- You have a type of wet AMD that hasn't been treated before, with fluid or swelling under the retina.
- Your vision in the study eye must be between 20/32 and 20/320 on an eye chart.
- You need to have a certain amount of central retinal thickness on an eye scan (OCT).
- You must be willing to use birth control and follow study procedures.
- You should not have certain health issues like uncontrolled high blood pressure, recent strokes, or serious heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
This study looks at how well the higher-dose eye injection aflibercept 8 mg works in people who have already had at least three earlier anti-VEGF injections for wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME). It tests if switching to this stronger dose is safe and effective in real-world care.
This trial tests a new medicine called RBS-001, given as an eye injection, against an approved treatment (Eylea) for wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the back of the eye; this study aims to see if the new drug works as well as the current standard.
This study tests a new eye injection (called QL1207H) against aflibercept, a standard treatment for wet macular degeneration. The goal is to see if the new drug is as effective in improving vision and reducing fluid in the eye.
Hear when a new nAMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.